160 related articles for article (PubMed ID: 14716145)
1. [Proapoptotic therapy with oblimersen (bcl-2 antisense oligonucleotide)--review of preclinical and clinical results].
Büchele T
Onkologie; 2003 Dec; 26 Suppl 7():60-9. PubMed ID: 14716145
[TBL] [Abstract][Full Text] [Related]
2. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
3. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
Frankel SR
Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
[TBL] [Abstract][Full Text] [Related]
4. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
Klasa RJ; Gillum AM; Klem RE; Frankel SR
Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702
[TBL] [Abstract][Full Text] [Related]
5. Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer.
Herbst RS; Frankel SR
Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4245s-4248s. PubMed ID: 15217967
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality.
Moreira JN; Santos A; Simões S
Rev Recent Clin Trials; 2006 Sep; 1(3):217-35. PubMed ID: 18473975
[TBL] [Abstract][Full Text] [Related]
7. Apoptosis, Bcl-2 antisense, and cancer therapy.
Piro LD
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):5-10. PubMed ID: 15651171
[TBL] [Abstract][Full Text] [Related]
8. Genasense (Genta Inc).
Banerjee D
Curr Opin Investig Drugs; 2001 Apr; 2(4):574-80. PubMed ID: 11566020
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 antisense therapy in multiple myeloma.
Chanan-Khan AA
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):21-4. PubMed ID: 15651173
[TBL] [Abstract][Full Text] [Related]
10. Oblimersen in the treatment of metastatic melanoma.
Tarhini AA; Kirkwood JM
Future Oncol; 2007 Jun; 3(3):263-71. PubMed ID: 17547520
[TBL] [Abstract][Full Text] [Related]
11. Potential therapeutic applications of oblimersen in CLL.
Koziner B
Oncology (Williston Park); 2004 Nov; 18(13 Suppl 10):32-8. PubMed ID: 15651175
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 antisense therapy in B-cell malignancies.
Chanan-Khan A
Blood Rev; 2005 Jul; 19(4):213-21. PubMed ID: 15784299
[TBL] [Abstract][Full Text] [Related]
13. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
[TBL] [Abstract][Full Text] [Related]
14. BCL-2 antisense oligonucleotide genasense is active against imatinib-resistant BCR-ABL-positive cells.
Tauchi T; Sumi M; Nakajima A; Sashida G; Shimamoto T; Ohyashiki K
Clin Cancer Res; 2003 Sep; 9(11):4267-73. PubMed ID: 14519654
[TBL] [Abstract][Full Text] [Related]
15. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.
van de Donk NW; Kamphuis MM; van Dijk M; Borst HP; Bloem AC; Lokhorst HM
Leukemia; 2003 Jan; 17(1):211-9. PubMed ID: 12529680
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy.
Kim R; Emi M; Tanabe K; Toge T
Cancer; 2004 Dec; 101(11):2491-502. PubMed ID: 15503311
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 antisense therapy in hematologic malignancies.
Chanan-Khan A
Curr Opin Oncol; 2004 Nov; 16(6):581-5. PubMed ID: 15627020
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies.
Galatin PS; Advani RH; Fisher GA; Francisco B; Julian T; Losa R; Sierra MI; Sikic BI
Invest New Drugs; 2011 Oct; 29(5):971-7. PubMed ID: 20349264
[TBL] [Abstract][Full Text] [Related]
19. Human Bcl-2 antisense therapy for lymphomas.
Cotter FE; Waters J; Cunningham D
Biochim Biophys Acta; 1999 Dec; 1489(1):97-106. PubMed ID: 10807000
[No Abstract] [Full Text] [Related]
20. Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides.
Tolcher AW
Clin Adv Hematol Oncol; 2005 Aug; 3(8):635-42, 662. PubMed ID: 16167050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
